Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma

NCT02519348 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02519348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02519348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 19, 2015
Completion date
December 18, 2026
Enrollment
433 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma